What's Happening?
Kyowa Kirin International has announced the appointment of Julie Dehaene-Puype as the new President for its International Region, effective November 1, 2025. Dehaene-Puype succeeds Jeremy Morgan, who will
retire at the end of December 2025 after a transition period. With over 25 years of experience in the global pharmaceutical industry, Dehaene-Puype brings extensive expertise in general management, commercial operations, and regulatory affairs. Her previous roles include positions at Mundipharma, Takeda, Merck/MSD, and Schering-Plough. She also serves as a Non-Executive Director on the board of Lytix Biopharma.
Why It's Important?
The leadership change at Kyowa Kirin International is significant as it marks a strategic move to strengthen the company's position in the global pharmaceutical market. Dehaene-Puype's appointment is expected to drive growth and innovation, particularly in the areas of rare diseases and oncology, which are key focus areas for the company. Her extensive experience and leadership skills are anticipated to enhance the company's operational efficiency and expand its market reach. This transition also reflects Kyowa Kirin's commitment to sustainable growth and its vision for 2030, aiming to deliver life-changing medicines.
What's Next?
As Dehaene-Puype assumes her new role, she will likely focus on advancing Kyowa Kirin's strategic initiatives and fostering partnerships to enhance the company's product pipeline. The transition period with outgoing President Jeremy Morgan will ensure continuity and stability within the organization. Stakeholders and industry observers will be watching for any strategic shifts or new initiatives that Dehaene-Puype may introduce to further the company's mission of delivering innovative healthcare solutions.
